Floatz logo

1,379 assets in Cancer

Therapeutic assets addressing Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
eik1004-001
Cancer
Eikon TherapeuticsP1/2CC (40)
eik1005
Cancer
Eikon TherapeuticsP1/2CC (40)
Eis-12656
Cancer
Eisbach Bio GmbHP1/2CC (40)
Envafolimab
Cancer
IR INNOVATE RESEARCH PRIVATE LIMITEDP1/2CC (40)
Epsametostat
Cancer
Haihe Biopharma Co., Ltd.P1/2CC (40)
Etx-636
Cancer
Ensem TherapeuticsP1/2CC (40)
FB849
Cancer
1ST Biotherapeutics, Inc.P1/2CC (40)
fl115
Cancer
Suzhou Forlong Biotechnology Co., LtdP1/2CC (40)
Gecacitinib
Cancer
Suzhou Zelgen Biopharmaceuticals Co.,LtdP1/2CC (40)
gen1286
Cancer
GenmabP1/2CC (40)
gfh375
Cancer
Genfleet Therapeutics (Shanghai) Inc.P1/2CC (40)
gi-101a
Cancer
GI Innovation, Inc.P1/2CC (40)
gi-102
Cancer
GI Innovation, Inc.P1/2CC (40)
gi-108
Cancer
GI Innovation, Inc.P1/2CC (40)
Gic-102
Cancer
GI Cell, Inc.P1/2CC (40)
gw5282
Cancer
Dizal PharmaceuticalsP1/2CC (40)
hb0028
Cancer
Shanghai Huaota Biopharmaceutical Co., Ltd.P1/2CC (40)
hb0036
Cancer
Shanghai Huaota Biopharmaceutical Co., Ltd.P1/2CC (40)
hec169096
Cancer
Sunshine Lake Pharma Co., Ltd.P1/2CC (40)
her2bbζ/cd19t+ t cells
Cancer
T-knife GmbHP1/2CC (40)
Hmbd-002
Cancer
Hummingbird BioscienceP1CC (40)
hrs2398
Cancer
Shanghai Hengrui Pharmaceutical Co., Ltd.P1/2CC (40)
Hrs-4642
Cancer
Jiangsu HengRui Medicine Co., Ltd.P1/2CC (40)
Hrs-6768
Cancer
Jiangsu HengRui Medicine Co., Ltd.P1/2CC (40)
hsk39775 monotherapy
Cancer
Xizang Haisco Pharmaceutical Co., LtdP1/2CC (40)
Human T-Lymphocyte Activation Antigen Cd80 (Activation B7-1 Antigen, Ctla-4 Counter-Receptor B7.1, Cd80) Extracellular Domain Containing Fragment (1-208 In The Current Sequence) Fused Via Peptide Linker <Sup>209</Sup>Gsggggsggggsggggs<Sup>225</Sup> To An Fc Fragment Of Human Immunoglobulin G4 (226-454) [Homo Sapiens Ighg4*01, Hinge Ins<Sup>226</Sup>>A, S<Sup>236</Sup>>P (226-238), Ch2 F<Sup>242</Sup>>A, L<Sup>243</Sup>>A, T<Sup>258</Sup>>Q (239-348), Ch3 M<Sup>436</Sup>>L (349-453), Chs K<Sup>455</Sup>>Del (454)] Fused Via Peptide/ Linker <Sup>455</Sup>Ggggs<Sup>459</Sup> To Human Interleukin-2 (Il-2, T-Cell Growth Factor (Tcgf)) (1-133, 460-592 In The Current Sequence), Variant (R<Sup>38</Sup>>A<Sup>497</Sup>, F<Sup>42</Sup>>A<Sup>501</Sup>), Dimer (234-234', 237-237')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Glycoform Alfa
Cancer
GI Innovation, Inc.P1/2CC (40)
hy05350 for
Cancer
Sichuan Huiyu Pharmaceutical Co., LtdP1/2CC (40)
(-)-Hydroxyurea Methylacylfulvene
Cancer
Lantern Pharma Inc.P1/2CC (40)
Idp-001
Cancer
InduPro, Inc.P1/2CC (40)
Ifinatamab Deruxtecan
Cancer
Merck Sharp & Dohme LLCP1/2CC (40)
imm01
Cancer
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.P1/2CC (40)
Imm-1-104
Cancer
Immuneering CorporationP1/2CC (40)
Immunoglobulin G1 [241-Aspartic Acid,334-Glutamic Acid], Anti-(Human/Mus Musculus/Macaca/Rattus Claudin Cldn18.2) (Human-Mus Musculus Monoclonal Lm-102 ?1-Chain), Disulfide With Human-Mus Musculus Monoclonal Lm-102 ?-Chain, Dimer
Cancer
LaNova Medicines Development Co., Ltd.P1/2CC (40)
Immunoglobulin G1-Kappa, Anti-[Homo Sapiens Erbb2 (Receptor Tyrosine-Protein Kinase Erbb-2, Epidermal Growth Factor Receptor 2, Egfr2, Her2, Her-2, P185C-Erbb2, Neu, Cd340)], Humanized Monoclonal Antibody, Conjugated At Glutaminyl Residues To Monomethylauristatin E (Mmae), With A Ratio Of 1 To 2, Via A Cleavable Linker
Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.P1/2CC (40)
Immunoglobulin G1-Kappa, Anti-[Homo Sapiens Il2 (Interleukin 2)], Homo Sapiens Antibody; Gamma1 Heavy Chain Homo Sapiens (1-451) [Vh (Homo Sapiens Ighv1-24*01 (84.5%) -(Ighd) -Ighj4*01 (92.9%), Cdr-Imgt [8.8.14] (26-33.51-58.97-110)) (1-121) -Homo Sapiens Ighg1*01, G1M17,1, G1V43 Ch2 A1.3, E1.2, A1 (Ch1 K120 (218) (122-219), Hinge 1-15 (220- 234), Ch2 L1.3>A (238), L1.2>E (239), (235- 344), Ch3 (345-449), Chs (450-451)) (122-451)], (224-220')-Disulfide With Kappa Light Chain Homo Sapiens (1'-220') [V-Kappa (Homo Sapiens Igkv4-1*01 (88.1%) -Igkj4*01 (90.9%), Cdr-Imgt [12.3.9] (27-38.56-58.95-103)) (1'-113') -Homo Sapiens Igkc*01 (100%), Km3, A45.1 (159), V101 (197) (114'- 220')]; Dimer(230-230'':233-233'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Derived From The Cell Line Cho-K1, Glycoform Alfa
Cancer
Aulos Bioscience, Inc.P1/2CC (40)
Immunoglobulin G4 [221-Proline], Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Sg001 ?4-Chain), Disulfide With Human Monoclonal Sg001 ?-Chain, Dimer
Cancer
CSPC Megalith Biopharmaceutical Co.,Ltd.P1/2CC (40)
imp1734
Cancer
Eikon TherapeuticsP1/2CC (40)
imp9064
Cancer
Impact Therapeutics, Inc.P1/2CC (40)
Imx-110
Cancer
Immix Biopharma, Inc.P1/2CC (40)
Incb177054
Cancer
Incyte CorporationP1/2CC (40)
ipg7236
Cancer
Nanjing Immunophage Biotech Co., LtdP1/2CC (40)
ipn01195
Cancer
IpsenP1/2CC (40)
ipn01203
Cancer
IpsenP1/2CC (40)
Jab-23E73
Cancer
Jacobio Pharmaceuticals Co., Ltd.P1/2CC (40)
js015
Cancer
Shanghai Junshi Bioscience Co., Ltd.P1/2CC (40)
js105
Cancer
Risen (Suzhou) Pharma Tech Co., Ltd.P1/2CC (40)
JS109
Cancer
Shanghai Jun Pai Ying Shi Therapeutics Co., Ltd.P1/2CC (40)
js207
Cancer
Wigen Biomedicine Technology (Shanghai) Co., Ltd.P1/2CC (40)
Jskn033
Cancer
Jiangsu Alphamab Biopharmaceuticals Co., LtdP1/2CC (40)
kl590586
Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.P1/2CC (40)
Showing 601 to 650 of 1,379 assets
PreviousPage 13 of 28Next